-
The 2022 CSCO | was full of wonderful and colorful flowers, and the special session on innovative drug clinical research data was held in Beijing
Time of Update: 2023-01-06
7. Professor Shi Yuankai: Phase II clinical study of Iruac (WX-0593) in the treatment of crizotinib-resistant/unused ROS1-positive non-small cell lung cancer patients with crizotinib This is an open-label, non-randomized, single-arm, multicenter, phase II clinical trial with primary endpoints of IRC-assessed ORR, and secondary endpoints including investigator-assessed ORR, DoR, DCR, PRF, TTP, intracranial objective response rate, OS, and adverse events.
-
The 2022 CSCO | was full of wonderful and colorful flowers, and the special session on innovative drug clinical research data was held in Beijing
Time of Update: 2023-01-06
7. Professor Shi Yuankai: Phase II clinical study of Iruac (WX-0593) in the treatment of crizotinib-resistant/unused ROS1-positive non-small cell lung cancer patients with crizotinib This is an open-label, non-randomized, single-arm, multicenter, phase II clinical trial with primary endpoints of IRC-assessed ORR, and secondary endpoints including investigator-assessed ORR, DoR, DCR, PRF, TTP, intracranial objective response rate, OS, and adverse events.
-
Professor Xu Bing: The treatment of FL should have a "strategic vision", and comprehensive consideration of treatment options is the key| the 7th International Summit Forum on Anti-leukemia
Time of Update: 2023-01-05
Follolar lymphoma (FL) is the most common indolent non-Hodgkin lymphoma, and first-line standard therapy significantly improves the prognosis of patients with FL, but FL is difficult to cure, and surv
-
Safety issues: Another company withdrew its indication for PARP inhibitors
Time of Update: 2022-11-25
On November 11, GSK announced for the second time that it withdrew some indications of the PARP inhibitor Zejula, which will be used only in patients with ovarian cancer with harmful and suspected harmful germline BRCA mutations in the second line.
-
Q&A related to the transition period of the food consumption period in Korea
Time of Update: 2022-10-02
Food Partner Network News Food consumer advertising circulation However, in reality, it is difficult to change the packaging of multiple products according to the implementation date, and discarding existing product packaging or pasting stickers will cause cost burden and waste of resources.
-
CDE releases new regulations for the development of anti-tumor drugs
Time of Update: 2021-12-06
The highest goal of new drug research and development is richer in connotation In July of this year, the "Guiding Principles" first appeared in the form of a draft for comments and aroused the attention of the industry.
-
Lancet Neurol: How effective and safe is gene replacement therapy for infant symptomatic spinal muscular atrophy type 1
Time of Update: 2021-11-02
Infections Recently, researchers have used broader eligibility criteria than those used by STR1VE-US to evaluate the safety and effectiveness of onasemnogene abeparvovec gene replacement therapy in infants with type 1 spinal muscular atrophy .
-
700 million cardiovascular injections market welcomes "spoilers" again
Time of Update: 2021-10-20
The reason why Qilu Pharmaceutical can occupy the main market is that the industry analysis believes that the main reason is that esmolol hydrochloride injection has the characteristics of fast onset and short action time, and it has a wide range of clinical use and large dosage.
-
Professor Ma Fei: Regarding the latest treatment progress in the field of breast cancer, you need to know
Time of Update: 2021-06-05
With these issues that the public and patients are most concerned about, the medical community has a dialogue with the authoritative expert-Professor Ma Fei, Director of the Internal Medicine Treatment Center of the National Cancer Center/Tumor Hospital of the Chinese Academy of Medical Sciences, and asked him to share his views on the diagnosis and treatment of breast cancer, and promote the public to this An understanding of malignant diseases.
-
Fujian's second round of centralized procurement: biological products are included in the group bidding, "soul bargaining" will reappear
Time of Update: 2021-04-14
In the Shandong Province bulk purchase in October 2020, recombinant human erythropoietin was also included in the centralized procurement catalog, and three companies won the bid.
-
Who will be the first Axl selective inhibitor to be marketed
Time of Update: 2021-03-23
In view of the multiple roles of AXL in tumor cells, the development of AXL inhibitors is considered to have two main directions, one is the treatment of drug-resistant tumors, and the other is Combined with the same "pass killing" immunotherapy, it can enhance the lethality against heterogeneous tumors.
-
How are genes regulated
Time of Update: 2021-03-14
this, the National Institutes of Health launched the GTEx project in 2010 to identify and map the association between quantitative marker points (QTLs), where genetic variation at specific locations of the genome is associated with gene expression in multiple tissues.
-
High blood sugar can lead to intestinal leakage and intestinal bacteria disorders
Time of Update: 2020-12-22
High blood sugar causes intestinal leakage To test whether elevated blood sugar levels were involved in regulating the function of the intestinal barrier, the researchers induced high blood sugar in mice without obesity, using a drug called streptococcus, which destroys islet β cells in mice, resulting in a phenomosis very similar to type 1 diabetes in humans.
-
Journal of Science: Tumor-targeted CD28 dual-specific antibodies enhance the anti-tumor effect of PD-1 immunotherapy
Time of Update: 2020-09-29
Janelle Waite and Dimitris Skokos, members of a larger Regeneron research team, are testing whether a class of co-irritating CD28 dual-specific antibodies enhances anti-tumor activity.
year, French scientists raised the issue of rotavirus vaccines that can be used to overcome cancer cell resistance to immune checkpoint blocking immunotherapy.
-
The United States accelerates the reduction of new coronavirus-targeted infections
Time of Update: 2020-09-15
Although more than 160,000 people have died in the U.S. today, and volunteers have a very low mortality rate from the new crown itself, not to mention a variant that reduces life, it is ethically questionable to appoint someone at a specified time and place to bear this even small risk of death.
